Cargando…

Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries

Recently, the need for health care services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (Re...

Descripción completa

Detalles Bibliográficos
Autores principales: Atikeler, Enver Kagan, Özçelikay, Gulbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081695/
https://www.ncbi.nlm.nih.gov/pubmed/27833835
http://dx.doi.org/10.1186/s40064-016-3455-z
_version_ 1782462933124513792
author Atikeler, Enver Kagan
Özçelikay, Gulbin
author_facet Atikeler, Enver Kagan
Özçelikay, Gulbin
author_sort Atikeler, Enver Kagan
collection PubMed
description Recently, the need for health care services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (Reference pricing: theory and evidence, reference pricing and pharmaceutical policy: perspectives on economics and innovation, springer, New York, pp 86–126, 2001), arrangements towards controlling the expenses through price and profit controls, reimbursement methods and incentives have recently gained wide currency. This present study examines; along with the current situation in Turkey, pharmaceutical pricing methods, reimbursement methods and basic health indicators, within the scope of changing pharmaceutical policies, in Turkey, the EU countries which Turkey takes as reference and the United Kingdom, the implementations of which are of utmost importance for other countries. Upon the research conducted, it was detected that the pharmaceutical pricing in Turkey has been performed on the basis of the reference pricing system that takes Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the reimbursement process are determined by SSI. For Turkey’s case; pricing and reimbursement system has been changed numerous times and the discount rates has incrementally risen. In pricing, on the other hand, during this period companies faced with difficulties in economic terms because of the fact that price discount of high rates are implemented over the reference price and that the European currency of Euro is determined as 70% of previous year average Euro sales rate which is 2,1166 for the year 2016. Each country has specific regulations and pricing and reimbursement policies of medicines based on economic situation, reimbursement methods and market size. The aim of pricing and reimbursement systems are reaching more efficient and sustainable healthcare systems.
format Online
Article
Text
id pubmed-5081695
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-50816952016-11-10 Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries Atikeler, Enver Kagan Özçelikay, Gulbin Springerplus Research Recently, the need for health care services has increased gradually and the limitations in sources allocated for this area have been recognized. Moving from this fact, it has gained a supreme importance to determine what health programs or technologies will be given priority. According to Danzon (Reference pricing: theory and evidence, reference pricing and pharmaceutical policy: perspectives on economics and innovation, springer, New York, pp 86–126, 2001), arrangements towards controlling the expenses through price and profit controls, reimbursement methods and incentives have recently gained wide currency. This present study examines; along with the current situation in Turkey, pharmaceutical pricing methods, reimbursement methods and basic health indicators, within the scope of changing pharmaceutical policies, in Turkey, the EU countries which Turkey takes as reference and the United Kingdom, the implementations of which are of utmost importance for other countries. Upon the research conducted, it was detected that the pharmaceutical pricing in Turkey has been performed on the basis of the reference pricing system that takes Italy, Portugal, Spain, Greece and France as reference. The regulations regarding the reimbursement process are determined by SSI. For Turkey’s case; pricing and reimbursement system has been changed numerous times and the discount rates has incrementally risen. In pricing, on the other hand, during this period companies faced with difficulties in economic terms because of the fact that price discount of high rates are implemented over the reference price and that the European currency of Euro is determined as 70% of previous year average Euro sales rate which is 2,1166 for the year 2016. Each country has specific regulations and pricing and reimbursement policies of medicines based on economic situation, reimbursement methods and market size. The aim of pricing and reimbursement systems are reaching more efficient and sustainable healthcare systems. Springer International Publishing 2016-10-26 /pmc/articles/PMC5081695/ /pubmed/27833835 http://dx.doi.org/10.1186/s40064-016-3455-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Research
Atikeler, Enver Kagan
Özçelikay, Gulbin
Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title_full Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title_fullStr Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title_full_unstemmed Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title_short Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries
title_sort comparison of pharmaceutical pricing and reimbursement systems in turkey and certain eu countries
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081695/
https://www.ncbi.nlm.nih.gov/pubmed/27833835
http://dx.doi.org/10.1186/s40064-016-3455-z
work_keys_str_mv AT atikelerenverkagan comparisonofpharmaceuticalpricingandreimbursementsystemsinturkeyandcertaineucountries
AT ozcelikaygulbin comparisonofpharmaceuticalpricingandreimbursementsystemsinturkeyandcertaineucountries